The Annals Take our Readership Survey!
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 27, No. 2, pp. 228-231.
© 1993 Harvey Whitney Books Company.
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hagley, M.
Right arrow Articles by Burns, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hagley, M.
Right arrow Articles by Burns, C.

Research Articles

Hepatotoxicity associated with angiotensin-converting enzyme inhibitors

MT Hagley, DT Hulisz, and CM Burns

OBJECTIVE: To review published reports of hepatotoxicity associated with angiotensin-converting enzyme (ACE) inhibitors and to explore possible mechanisms of injury. DATA SOURCES: Published reports of hepatotoxicity associated with use of ACE inhibitors and investigations that suggest potential mechanisms of injury. DATA SYNTHESIS: Nineteen cases of ACE-inhibitor-associated hepatotoxicity are presented. Early theories regarding mechanisms are reviewed. Laboratory investigations of hepatic effects of eicosanoids on hepatic function are reviewed and a novel mechanism by which ACE inhibitors may cause hepatic injury is postulated. CONCLUSIONS: Hepatotoxicity, usually cholestatic in nature, has been reported with captopril, enalapril, and lisinopril use. Apparent cross-reactivity has been reported twice. Potential mechanisms of injury include idiopathic hypersensitivity and modulation of eicosanoid metabolism by inhibition of kininase II and subsequent increased hepatic bradykinin activity. Mediation via altered eicosanoid metabolism provides a plausible explanation for cross-reactivity among ACE inhibitors. Hepatotoxicity resolves if ACE inhibitors are stopped but may progress to liver failure if treatment is continued.


This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
J.-W. Chou, C.-J. Yu, P.-H. Chuang, H.-C. Lai, C.-H. Hsu, K.-S. Cheng, C.-Y. Peng, and I-P. Chiang
Successful Treatment of Fosinopril-Induced Severe Cholestatic Jaundice with Plasma Exchange
Ann. Pharmacother., December 1, 2008; 42(12): 1887 - 1892.
[Abstract] [Full Text] [PDF]

Home page
 Canadian J. AnesthesiaHome page
A. Lehmann, M. Neher, A.-H. Kiessling, F. Isgro, A. Koloska, and J. Boldt
Case report: Fatal hepatic failure after aortic valve replacement and sevoflurane exposure: [Presentation de cas : Insuffisance hepatique fatale apres un remplacement de la valve aortique et une exposition au sevoflurane]
Can J Anesth, November 1, 2007; 54(11): 917 - 921.
[Abstract] [Full Text] [PDF]

Home page
 ICVTSHome page
R. Svedjeholm, E. Hakanson, M. Lindstrom, and P. Hjort
Post-infarct left ventricular free wall rupture and ventricular septal defect managed by pericardial aspiration during transport to referral hospital
Interactive CardioVascular and Thoracic Surgery, June 1, 2003; 2(2): 193 - 195.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
R Hariraj, E Stoner, S Jader, and D M Preston
Drug points: Prolonged cholestasis associated with irbesartan
BMJ, September 2, 2000; 321(7260): 547 - 547.
[Full Text]


homecopy help contact us subscription past issues search current issue
Copyright © 1993 by Harvey Whitney Books Company.